Essa Shares Plummet as Merger Terms Are Slashed

Investors in Essa have reacted harshly to a severe downgrade in the proposed terms for its business combination with XenoTherapeutics. The announcement has triggered a significant sell-off, eroding shareholder confidence and driving the stock price sharply lower.

Market Reaction and Share Price Decline

The negative sentiment was immediately reflected in the market. Essa’s stock tumbled nearly 9.69% over the past 24-hour period, bringing its weekly loss to approximately 7.26%. The most dramatic move occurred in pre-market trading following the news, where shares plummeted by 17%, indicating a decisive punitive response from the investment community.

Should investors sell immediately? Or is it worth buying Essa?

Drastic Reduction in Shareholder Payouts

The core issue lies in the radically altered conditions of the merger. Shareholders are now set to receive a cash dividend of just $0.12 per share, a staggering reduction from the initially anticipated payout of around $1.91 per share. As a partial concession, one contingent value right (CVR) per share will also be issued. However, this CVR carries significant uncertainty, with a maximum potential value of only $0.14, contingent on the resolution of certain liability matters.

Key Developments for Shareholders

• Severe Dividend Cut: The per-share cash payment has been slashed from $1.91 to $0.12.
• Uncertain Value: An additional CVR per share offers a maximum potential of $0.14, subject to liabilities.
• Sharp Price Decline: The stock fell almost 10% in a single day and over 7% for the week.
• Meeting Postponed: The special shareholder meeting has been rescheduled for October 3, 2025.
• Strategic Pivot: The company is now focusing on liquidation instead of drug development.

Shareholder Meeting Delayed and Strategic Shift

To allow investors more time to evaluate the fundamentally changed merger terms, the company has postponed its extraordinary general meeting to October 3, 2025. Essa is also seeking an amended interim order from the Supreme Court of British Columbia. This shift follows a strategic change in direction, confirmed by the $1.69 per share special dividend paid in August and the discontinuation of its prostate cancer research program. The company is now concentrating on managing existing assets, marking a definitive end to its growth narrative centered on pharmaceutical development.